Skip to main content

Context Therapeutics Inc.

For the period ended Jun 30, 2025. Filed Aug 6, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 6, 2025

CNTX$0.19-6.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

Six Months Ended June 30,
20252024
Cash flows from operating activities:
Net loss$(13,404,771)$(5,922,303)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense682,831397,044
Depreciation and amortization expense8,1205,136
Reduction in the carrying amount of operating lease right-of-use asset52,737—
Changes in operating assets and liabilities:
Prepaid expenses and other current assets34,972435,751
Accounts payable958,960(1,816,135)
Accrued expenses and other current liabilities855,651(815,867)
Operating lease liability(52,061)—
Cash used in operating activities(10,863,561)(7,716,374)
Cash flows from investing activities:
Purchase of property and equipment(33,948)—
Cash used in investing activities(33,948)—
Cash flows from financing activities:
Payment of offering costs from the sale of common stock from ATM facility(15,268)—
Proceeds from the sale of common stock and prefunded warrants, net—94,803,379
Cash (used in) provided by financing activities(15,268)94,803,379
Net (decrease) increase in cash and cash equivalents(10,912,777)87,087,005
Cash and cash equivalents at beginning of period94,429,82414,449,827
Cash and cash equivalents at end of period$83,517,047$101,536,832
Supplemental disclosure of non-cash activities:
Unpaid offering costs in accounts payable$—$44,632
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.